Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome
The DOI matches its Crossref record.
Abstract
BACKGROUND: Recently the pathophysiological role of endothelin (ET) has been presumed in a number of adrenal disorders such as primary hyperaldosteronism, pheochromocytoma and adrenocortical insufficiency. AIM: The aim of the present study was to evaluate circulating ET-1 levels in patients with endogenous Cushing's syndrome. METHODS AND RESULTS: Plasma ET-1 levels were determined by highly sensitive RIA. Thirteen untreated subjects with Cushing's syndrome were studied: eight women and five men of mean age 44.2+/-9.5 Years (s.d.). In ten of them, Cushing's disease had been diagnosed and three had adrenal adenomas. ET-1 was 3-fold higher in the patient group than in age-matched healthy controls (n=13): 1.59+/-0.78 vs 0.46+/-0.20 pmol/l respectively, P<0.001. In adrenal adenoma patients, ET-1 was not significantly higher than in the Cushing's disease subjects (1.84+/-0.67 vs 1.51+/-0.83 pmol/l respectively, P>0.05). In three patients who died of severe cardiovascular complications, plasma ET-1 was significantly higher than in the remaining patients (2.34+/-0.35 pmol/l, P<0.05). A positive correlation was found between the total cholesterol (6.94+/-1.75 mmol/l) and ET-1 levels in the patients with Cushing's syndrome: r=+0.73, P<0.02. No correlation was observed, however, between the levels of ET-1 and blood pressure (183+/-37/106+/-18 mmHg), plasma cortisol levels (455.2+/-74.5 nmol/l) or urinary cortisol excretion (1463+/-726 nmol/24 h). The successful treatment and correction of hypercortisolism in seven patients led to insignificant reduction in plasma ET from 1.34+/-0.69 to 0.73+/-0.53 pmol/l, P>0.05. CONCLUSION: Our results clearly demonstrate that the ET system is activated in Cushing's syndrome. Elevated plasma ET-1 levels probably play a role in the pathogenesis of accelerated and early atherosclerosis development in this disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The Pathogenetic Role of Cortisol in the Metabolic Syndrome: A Hypothesis
Anagnostis, P., Athyros, V. G., Tziomalos, K., Karagiannis, A., & Mikhailidis, D. P. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0370 · Cited by 613
Cardiovascular consequences of cortisol excess
Whitworth, J. A., Williamson, P. M., Mangos, G., & Kelly, J. J. (2005) · Vascular Health and Risk Management · doi:10.2147/vhrm.2005.1.4.291 · Cited by 392
MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis
Morand, E. F., Leech, M., & Bernhagen, J. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2029 · Cited by 351
Hypertension in Cushing’s Syndrome: From Pathogenesis to Treatment
Cicala, M. V., & Mantero, F. (2010) · Neuroendocrinology · doi:10.1159/000314315 · Cited by 112
“Enhancement of Cardiovascular Reactivity to Vasoconstrictors Endothelin-1 (ET-1), the most potent vasoconstrictor peptide with marked hypertensive, mitogenic and atherogenic effects, is significantly elevated in patients with untreated active CS. A trend towards reduction in plasma ET was observed in the patients afte…”
BackgroundCardiovascular risk in Cushing’s syndrome
Arnaldi, G., Mancini, T., Polenta, B., & Boscaro, M. (2004) · Pituitary · doi:10.1007/s11102-005-1172-7 · Cited by 103
“Plasma concentrations in this peptide, a potent vasoconstrictor with hypertensive, mitogenic and atherogenic effects, were found to be significantly high in patients with hypercortisolism and decreased after disease remission [17].”
Background
Metadata
- Authors
- Kirilov, G., Tomova, A., Dakovska, L., Kumanov, P., Shinkov, A., & Alexandrov, A.
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-12-01
- Volume
- 149
- Issue
- 6
- Pages
- 549-553
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2159021459
- Cited by
- 64
- References
- 0
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome. https://app.cochat.ai/papers/10.1530/eje.0.1490549
- The paper
- Kirilov, G., Tomova, A., Dakovska, L., Kumanov, P., Shinkov, A., & Alexandrov, A. (2003). Elevated plasma endothelin as an additional cardiovascular risk factor in patients with Cushing's syndrome. European Journal of Endocrinology. https://doi.org/10.1530/eje.0.1490549
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.